Your Pain Is Real, Your Genes May Be Amplifying It.

Your COMT gene encodes an enzyme that breaks down dopamine and norepinephrine, two neurotransmitters central to pain inhibition. When COMT is working normally, it maintains a balanced level of these chemicals in your prefrontal cortex, the brain region that suppresses pain signals. This is how your brain naturally turns down the volume on pain.

The Val158Met variant, carried by roughly 25% of people of European ancestry in the homozygous slow form, significantly impairs COMT enzyme function. People with the slow variant accumulate dopamine and norepinephrine, paradoxically making them hypersensitive to pain signals rather than pain-resistant. You might expect extra dopamine to feel good, but in the context of pain processing, the dysregulation amplifies the trigeminal and spinal pain pathways.

You notice this as a lower pain threshold. A light touch feels sharp. Background noise becomes piercing. Your nervous system can’t properly inhibit pain signals, so they cascade unchecked. You may feel wired and anxious under stress, and pain flares become more intense when you’re emotionally activated.

Your OPRM1 gene codes for the mu-opioid receptor, which sits on neurons throughout your pain processing system and spinal cord. When endogenous opioids (your body’s natural painkillers, called endorphins and enkephalins) bind to this receptor, they suppress pain signals. This is your internal morphine system, active during exercise, social connection, and moments of safety.

The A118G variant, present in roughly 10-15% of people of European ancestry and much higher in East Asian populations, reduces the receptor’s sensitivity to endogenous opioids. Your opioid receptors require a higher concentration of your body’s natural painkillers to activate, meaning your baseline pain-relief capacity is dampened. You’re essentially born with a lower “volume dial” on your internal pain suppression.

You experience this as a stubbornly high baseline pain level and reduced response to activities that normally soothe pain (exercise, social warmth, relaxation). You may find that standard opioid medications are less effective, or that you need higher doses. Your pain doesn’t ease as quickly as others’, even when triggers are removed.

Your MTHFR gene encodes methylenetetrahydrofolate reductase, an enzyme that converts folate into its active form and sits at the center of your methylation cycle. This cycle controls nitric oxide production, a signaling molecule that regulates vascular tone and neuronal excitability. Impaired methylation also raises homocysteine, which irritates blood vessel walls and increases neuroinflammation.

The C677T variant, carried by roughly 40% of people of European ancestry, reduces MTHFR enzyme efficiency by 40-70%. You may have normal folate intake and normal blood folate levels, yet your cells are unable to convert it into the usable form, leaving you functionally deficient at the cellular level. This impairs nitric oxide production and methylation-dependent processes throughout your nervous system, including pain signal processing.

You experience this as elevated baseline inflammation in pain-processing regions, exaggerated pain responses to minor stimuli, and slow recovery after pain flares. Your central nervous system remains in a state of chronic irritability. Homocysteine elevation also damages blood vessel walls, worsening oxygen delivery to affected tissues.

Your BDNF gene codes for brain-derived neurotrophic factor, a protein that shapes how your pain processing circuits develop and adapt. BDNF is central to neuroplasticity, the brain’s ability to rewire itself. In pain circuits, BDNF strengthens synaptic connections between pain neurons, essentially hard-wiring pain pathways. Normally this is adaptive, but in central sensitization, BDNF becomes overactive, cementing hypersensitivity into your nervous system.

The Val66Met variant, carried by roughly 30% of the population who inherit the Met allele, alters BDNF release and activity. Met carriers have reduced BDNF-dependent pain pathway plasticity, but paradoxically are more susceptible to developing central sensitization once triggered, because their pain circuits become “stuck” in a hypersensitive state. Val carriers can also experience heightened pain responses in the acute phase, but their circuits are more flexible and recover faster.

You experience this as pain that doesn’t seem to resolve proportionally to healing. An injury from months ago still feels acute. Your nervous system doesn’t seem to downregulate pain signals the way it should. You may notice that your pain is disproportionate to tissue damage, and that once a pain pattern develops, it’s remarkably hard to shift.

Your TRPV1 gene codes for a heat and pain-sensing ion channel found on sensory neurons throughout your body. This receptor detects heat, capsaicin (spicy), and inflammatory signals like low pH. Once activated, it fires pain signals up to your spinal cord and brain. TRPV1 is essential for normal pain detection, but when it has a low activation threshold, even mild warmth or chemical irritation triggers pain.

Certain TRPV1 variants, present in roughly 25-30% of the population, lower the activation threshold for this receptor. Your sensory neurons fire pain signals at temperatures and pressures that would not trigger pain in others, meaning your baseline sensory input is already amplified before it reaches your spinal cord and brain. You’re starting the pain processing cascade at a higher baseline.

You notice this as exaggerated responses to heat, cold, pressure, and chemical irritants (spicy foods, strong perfumes, certain fabrics). A warm shower feels burning. A tight hug feels painful. Even light pressure, like wearing socks, can be uncomfortable. Your sensory neurons are doing their job perfectly; they’re just set to “sensitive” by default.

Your GCH1 gene encodes GTP cyclohydrolase 1, an enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for three pain-modulating neurotransmitters: dopamine, serotonin, and nitric oxide synthase. Without adequate BH4, these neurotransmitter pathways cannot produce sufficient amounts of dopamine, serotonin, and nitric oxide. It’s like trying to manufacture a product when you’re missing a key ingredient.

Certain GCH1 variants, present in roughly 15-20% of the population, reduce BH4 synthesis capacity. You may have normal genes for dopamine and serotonin production, but insufficient cofactor to actually manufacture them, leaving you functionally depleted in all three pain-modulating systems simultaneously. Your brain is trying to suppress pain with insufficient raw materials.

You experience this as a relentless, multi-system pain sensitivity. Pain thresholds are low across your body. Medications targeting single neurotransmitters (like SSRIs for serotonin) may provide only partial relief because the bottleneck is upstream, at the BH4 level. You may feel like multiple things are “wrong” with your pain processing.